Astrazeneca (AZN) Enterprise Value (2016 - 2025)
Astrazeneca has reported Enterprise Value over the past 11 years, most recently at -$5.8 billion for Q4 2025.
- Quarterly results put Enterprise Value at -$5.8 billion for Q4 2025, down 363.34% from a year ago — trailing twelve months through Dec 2025 was -$5.8 billion (down 363.34% YoY), and the annual figure for FY2025 was -$5.8 billion, down 363.34%.
- Enterprise Value for Q4 2025 was -$5.8 billion at Astrazeneca, down from -$1.3 billion in the prior quarter.
- Over the last five years, Enterprise Value for AZN hit a ceiling of -$1.3 billion in Q4 2024 and a floor of -$6.4 billion in Q4 2021.
- Median Enterprise Value over the past 5 years was -$6.0 billion (2023), compared with a mean of -$5.1 billion.
- Biggest five-year swings in Enterprise Value: crashed 384.29% in 2021 and later surged 78.98% in 2024.
- Astrazeneca's Enterprise Value stood at -$6.4 billion in 2021, then increased by 2.48% to -$6.3 billion in 2022, then rose by 4.75% to -$6.0 billion in 2023, then surged by 78.98% to -$1.3 billion in 2024, then plummeted by 363.34% to -$5.8 billion in 2025.
- The last three reported values for Enterprise Value were -$5.8 billion (Q4 2025), -$1.3 billion (Q4 2024), and -$6.0 billion (Q4 2023) per Business Quant data.